2.Effectiveness of vacuum-assisted closure (VAC) therapy in the healing of chronic diabetic foot ulcers.
Aziz NATHER ; Siok Bee CHIONH ; Audrey Y Y HAN ; Pauline P L CHAN ; Ajay NAMBIAR
Annals of the Academy of Medicine, Singapore 2010;39(5):353-358
INTRODUCTIONThis is the fi rst prospective study done locally to determine the effectiveness of vacuum-assisted closure (VAC) therapy in the healing of chronic diabetic foot ulcers.
MATERIALS AND METHODSAn electronic vacuum pump was used to apply controlled negative pressure evenly across the wound surface. Changes in wound dimension, presence of wound granulation and infection status of diabetic foot ulcers in 11 consecutive patients with diabetes were followed over the course of VAC therapy.
RESULTSHealing was achieved in all wounds. Nine wounds were closed by split-skin grafting and 2 by secondary closure. The average length of treatment with VAC therapy was 23.3 days. Ten wounds showed reduction in wound size. All wounds were satisfactorily granulated and cleared of bacterial infection at the end of VAC therapy.
CONCLUSIONSVAC therapy was useful in the treatment of diabetic foot infection and ulcers, which after debridement, may present with exposed tendon, fascia and/or bone. These included ray amputation wounds, wounds post-debridement for necrotising fasciitis, wounds post-drainage for abscess, a heel ulcer and a sole ulcer. It was able to prepare ulcers well for closure via split-skin grafting or secondary closure in good time. This reduced cost of VAC therapy, as therapy was not prolonged to attain greater reduction in wound area. VAC therapy also provides a sterile, more controlled resting environment to large, exudating wound surfaces. Large diabetic foot ulcers were thus made more manageable.
Adult ; Debridement ; Diabetic Foot ; classification ; surgery ; therapy ; Female ; Humans ; Male ; Middle Aged ; Negative-Pressure Wound Therapy ; Prospective Studies ; Wound Healing
3.Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.
Khean Lee GOH ; Myung Gyu CHOI ; Ping I HSU ; Hoon Jai CHUN ; Varocha MAHACHAI ; Udom KACHINTORN ; Somchai LEELAKUSOLVONG ; Nayoung KIM ; Abdul Aziz RANI ; Benjamin C Y WONG ; Justin WU ; Cheng Tang CHIU ; Vikram SHETTY ; Joseph C BOCOBO ; Melchor M CHAN ; Jaw Town LIN
Journal of Neurogastroenterology and Motility 2016;22(3):355-366
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.
Asia*
;
Blood Platelets
;
Delayed-Action Preparations
;
Delivery of Health Care
;
Dexlansoprazole*
;
Efficiency
;
Esophagitis
;
Gastroesophageal Reflux*
;
Healthy Volunteers
;
Plasma
;
Prevalence
;
Proton Pump Inhibitors
;
Proton Pumps*
;
Protons*
6.Asian society of gynecologic oncology workshop 2010.
Dong Hoon SUH ; Jae Weon KIM ; Mohamad Farid AZIZ ; Uma K DEVI ; Hextan Y S NGAN ; Joo Hyun NAM ; Seung Cheol KIM ; Tomoyasu KATO ; Hee Sug RYU ; Shingo FUJII ; Yoon Soon LEE ; Jong Hyeok KIM ; Tae Joong KIM ; Young Tae KIM ; Kung Liahng WANG ; Taek Sang LEE ; Kimio USHIJIMA ; Sang Goo SHIN ; Yin Nin CHIA ; Sarikapan WILAILAK ; Sang Yoon PARK ; Hidetaka KATABUCHI ; Toshiharu KAMURA ; Soon Beom KANG
Journal of Gynecologic Oncology 2010;21(3):137-150
This workshop was held on July 31-August 1, 2010 and was organized to promote the academic environment and to enhance the communication among Asian countries prior to the 2nd biennial meeting of Australian Society of Gynaecologic Oncologists (ASGO), which will be held on November 3-5, 2011. We summarized the whole contents presented at the workshop. Regarding cervical cancer screening in Asia, particularly in low resource settings, and an update on human papillomavirus (HPV) vaccination was described for prevention and radical surgery overview, fertility sparing and less radical surgery, nerve sparing radical surgery and primary chemoradiotherapy in locally advanced cervical cancer, were discussed for management. As to surgical techniques, nerve sparing radical hysterectomy, optimal staging in early ovarian cancer, laparoscopic radical hysterectomy, one-port surgery and robotic surgery were introduced. After three topics of endometrial cancer, laparoscopic surgery versus open surgery, role of lymphadenectomy and fertility sparing treatment, there was a special additional time for clinical trials in Asia. Finally, chemotherapy including neo-adjuvant chemotherapy, optimal surgical management, and the basis of targeted therapy in ovarian cancer were presented.
Asia
;
Asian Continental Ancestry Group
;
Chemoradiotherapy
;
Endometrial Neoplasms
;
Female
;
Fertility
;
Humans
;
Hysterectomy
;
Laparoscopy
;
Lymph Node Excision
;
Mass Screening
;
Ovarian Neoplasms
;
Uterine Cervical Neoplasms
;
Vaccination